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The receptor tyrosine kinase ErbB is activated by ligand-induced dimerization, leading to trans-
phosphorylation of the cytoplasmic kinase domains. Bill et al. (2010) now demonstrate that trans-
phosphorylation can be modulated from within the cell by the cytoplasmic protein cytohesin,
providing new insights into ErbB-dependent processes during normal development and cancer.Receptor tyrosine kinases (RTKs) are
a large family of single-pass transmem-
brane receptors that convert extracellular
information, conveyed by ligands, to
the activation of intracellular signaling
cascades. Ligand binding induces
receptor dimerization and leads to trans-
phosphorylation of tyrosines in the
cytoplasmic kinase domains. The phos-
phorylation creates docking sites for SH2
domains, thus recruiting to the activated
receptor complex proteins that trigger
intracellular signal transductioncascades.
A variety of positive and negative regula-
tory interactions affect the signaling
outcome. The mechanisms include ubiq-
uitination and phoshorylation of the
receptor, formation of nonproductive
receptor dimers, trapping of the extracel-
lular ligand, andmodulationof the intracel-
lular cascade. However, until now, no
cytoplasmic components were known to
directly affect the process of ligand-
induced receptor phosphorylation. Bill
et al. (2010) now show that cytohesins,
guanine nucleotide exchange factors
(GEFs), bind to the cytoplasmic domain
of ErbB receptor dimers and facilitate
conformational changes that promote
transphosphorylation and signaling
activity.
These findings add to an increasingly
complex and nuanced understanding of
the mechanisms of receptor tyrosine
kinase activation. It was originally pro-
posed that communication between the
extracellular and intracellular domains of
RTKs is sequential, that is, dimerization
of the extracellular domains, triggered by
ligand binding, leads to dimerization of
the intracellular domains and subsequent
kinase activation (Yarden and Schles-
singer, 1987). However, further work hassince revealed several surprising new
features of RTK dimerization, a process
that has been examined in the greatest
detail for the epidermal growth factor
(EGF) receptor/ErbB family. In the case
of the Drosophila EGF receptor dimer,
binding of the first ligand molecule
induces a conformational change that
reduces the affinity for binding of the
second ligand molecule (Alvarado et al.,
2010). The cytoplasmic juxtamembrane
region also plays a role in activation of
the kinase (Red Brewer et al., 2009; Thiel
and Carpenter, 2007). Ligand binding
relieves an inhibitory association between
the juxtamembrane region and the kinase
domain, facilitating dimerization between
the two juxtamembrane domains that
stabilizes the kinase domain dimer (Jura
et al., 2009). Finally, recent work shows
that kinase domains exist in an autoinhi-
bited state. Activation of the kinase
requires generation of an asymmetric
dimer, where the C-terminal lobe of one
kinase molecule activates the second
kinase domain (Zhang et al., 2006). An
extreme case of dimer asymmetry occurs
in the formation of active heterodimeric
ErbB complexes that comprise one
receptor with an active kinase domain
and one with a catalytically dead kinase
domain (ErbB3).
One question, therefore, is whether and
how cells regulate these additional steps
in the activation of RTKs. A recent study
on Dok-7, an SH2-containing adaptor
protein for the MuSK RTK, suggested
that Dok-7 facilitates MuSK activity by
promoting the juxtaposition of the
two kinase domains, forming a positive
feedback loop. This loop enhances
receptor activation in distinct domains
along the muscle plasma membraneCell 143at neuromuscular junctions (Bergamin
et al., 2010; Inoue et al., 2009).
The paper by Bill et al. (2010) identifies
a new scenario in which cytoplasmic
components impinge on the process of
RTK activation. The work demonstrates
that cytohesins play a critical role of facil-
itating ErbB receptor family activation.
Cytohesin proteins were previously char-
acterized as guanine nucleotide ex-
change factors for ADP ribosylation
factors (ARFs). Interestingly, GEF activity
is dispensable for their role in fa-
cilitating ErbB activation. Bill et al. (2010)
show that the level of cytohesins directly
affects the signaling outcome of ErbB
receptors (Figure 1). Although overex-
pression of cytohesins does not affect
EGF receptor clustering or endocytosis,
it leads to an increase in the phosphoryla-
tion of EGF receptor dimers. Conversely,
inhibition of cytohesin with the specific
inhibitor SecinH3 reduces the phosphory-
lation of dimerized receptors. Further-
more, fluorescence resonance energy
transfer (FRET) studies of EGF receptor
dimers tagged with a fluorescent protein
suggest that the addition of cytohesin
leads to conformational changes in the
cytoplasmic domains. These changes
affect kinase activation, presumably by
facilitating structural changes required
for formation of an asymmetric kinase
dimer.
This study is important because it iden-
tifies a new way for the signal-receiving
cell to modify the RTK signal early in the
signaling process, at the level of receptor
phosphorylation. And as may be ex-
pected, cancer cells point theway topath-
ological abrogation of this circuit. Elevated
EGF receptor/ErbB signaling is character-
istic of many cancers. Bill et al. show that, October 15, 2010 ª2010 Elsevier Inc. 181
Figure 1. Cytohesin Levels Modulate ErbB Dimer Phosphorylation
(A) Upon ligand binding, ErbB receptor tyrosine kinases form dimers. In order to activate the kinase
domain and trigger transphosphorylation, conformational changes that induce formation of asymmetric
dimersmust take place. Direct binding of cytohesin to the cytoplasmic domain facilitates these conforma-
tional changes.
(B) Overexpression of cytohesins, which occurs in some lung adenocarcinomas, elevates EGF receptor
phosphorylation.
(C) Reduction in cytohesin levels, for example following treatment with the drug SecinH3 or cytohesin RNA
interference, leads to a decrease in receptor phosphorylation.there is an increase in ErbB transphos-
phorylation in human lung adenocarci-
nomas with elevated levels of cytohesins,
without a corresponding increase in
receptor protein levels. These observa-
tions raise the possibility of attenuating
ErbB activity in tumors by antagonizing
cytohesins. Indeed, Bill et al. show that182 Cell 143, October 15, 2010 ª2010 Elseviaddition of SecinH3 reduced the prolifera-
tion of an EGF receptor-dependent lung
cancer cell line. When the same cells
were injected into mice, treatment of the
mice with the inhibitor also resulted in
reduced proliferation of tumor cells.
Similar modulations of RTK activity
from within the cell may also occur duringer Inc.normal organismal development to adjust
the responsiveness of tissues to a given
RTK signaling pathway. In Drosophila,
for example, immunohistochemical stain-
ing for the activated form of MAP kinase
has shown dramatic differences among
tissues in the range of EGF receptor
signaling activity around a ligand source
(Gabay et al., 1997). In some tissues, the
range of signaling is clearly modulated
by the level of active ligand. However, it
now seems feasible that the local level of
cytohesins or other, yet to be identified
cytoplasmic modulators also determines
the sensitivity of individual tissues to
EGF receptor activation.REFERENCES
Alvarado, D., Klein, D.E., and Lemmon, M.A.
(2010). Cell 142, 568–579.
Bill, A., Schmitz, A., Albertoni, B., Song, J.-N., Heu-
kamp, L.C., Walrafen, D., Thorwith, F., Verveer,
P.J., Zimmer, S., et al. (2010). Cell 143, this issue,
201–211.
Bergamin, E., Hallock, P.T., Burden, S.J., and Hub-
bard, S.R. (2010). Mol. Cell 39, 100–109.
Gabay, L., Seger, R., and Shilo, B.Z. (1997).
Science 277, 1103–1106.
Inoue, A., Setoguchi, K., Matsubara, Y., Okada, K.,
Sato, N., Iwakura, Y., Higuchi, O., and Yamanashi,
Y. (2009). Sci. Signal. 2, ra7.
Jura, N., Endres, N.F., Engel, K., Deindl, S., Das,
R., Lamers, M.H., Wemmer, D.E., Zhang, X., and
Kuriyan, J. (2009). Cell 137, 1293–1307.
Red Brewer, M., Choi, S.H., Alvarado, D., Morav-
cevic, K., Pozzi, A., Lemmon, M.A., and Carpenter,
G. (2009). Mol. Cell 34, 641–651.
Thiel, K.W., and Carpenter, G. (2007). Proc. Natl.
Acad. Sci. USA 104, 19238–19243.
Yarden, Y., and Schlessinger, J. (1987). Biochem-
istry 26, 1434–1442.
Zhang, X., Gureasko, J., Shen, K., Cole, P.A., and
Kuriyan, J. (2006). Cell 125, 1137–1149.
